Details of the events are as follows:
- 10th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on
Wednesday, January 6 throughFriday, January 8 andMonday, January 11 throughThursday, January 14, 2021 . H.C. Wainwright Virtual BioConnect Conference : The company’s presentation will be available for on-demand viewing on Checkpoint’s website beginningMonday, January 11, 2021 , at6:00 a.m. EST .- B. Riley Securities’
Virtual Oncology Investor Conference : The company’s presentation will take place onThursday, January 21, 2021 , at10 a.m. EST and will be available to all conference-registered institutional investors.
Webcasts of the H.C. Wainwright and
About
Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our plans to submit one or more Biologics License Applications and seek approvals for cosibelimab, statements regarding the potential differentiation of cosibelimab, including a potentially favorable safety profile as compared to the currently available anti-PD-1 therapies, statements relating to the half-life and functional Fc domain of cosibelimab translating into potential enhanced efficacy, statements relating to the timing of the completion of enrollment and full top-line results, statements relating to how long we believe our cash will fund our operations, any statements relating to our growth strategy, product development programs and commercial prospects, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks that regulatory authorities will not accept an application for approval of cosibelimab based on data from the ongoing Phase 1 study; risks relating to our growth strategy and commercial prospects; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
Company Contacts:
(781) 652-4500
ir@checkpointtx.com
Investor Relations Contact:
Managing Director,
(617) 430-7577
arr@lifesciadvisors.com
Media Relations Contact:
Affect
(212) 398-9680
ekraft@affect.com
2021 GlobeNewswire, Inc., source